Tagrisso plus chemotherapy shows nearly four-year median overall survival in lung cancer trial
AstraZeneca's Tagrisso combined with chemotherapy demonstrated a median overall survival of nearly four years in advanced EGFR-mutated lung cancer, according to final Phase III trial results.
AstraZeneca announced that its drug Tagrisso (osimertinib) when used in combination with chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival (OS) for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) receiving first-line treatment.
The final analysis of the FLAURA2 Phase III trial revealed a median OS of 47.5 months for the Tagrisso plus chemotherapy arm, compared to 37.6 months for Tagrisso monotherapy. This represents a 23% reduction in the risk of death for patients treated with the combination.
These findings were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC) in Barcelona. The results reinforce Tagrisso's role as a standard of care and backbone therapy in EGFR-mutated lung cancer.
David Planchard, MD, PhD, an oncologist involved in the trial, stated that the combination therapy aims to extend survival while preserving patients' quality of life. AstraZeneca noted that these results set a new survival standard for patients in this treatment setting.